Starlink V5 Arrives Quietly SpaceX released its V5 residential dish this week without much noise, and it does

The next test flight of SpaceX's Starship spacecraft and Super Heavy booster could take off as soon as Thursday, and much of the hour-long mission will look a lot like the last Starship flight in May.

But there are a few key differences for this launch, set to occur during a launch window that opens at 5:45 pm CDT (22:45 UTC) on Thursday. The most notable change is the inclusion of real, functioning Starlink satellites inside Starship's cargo bay. SpaceX previously tested the ship's payload deployment mechanism using simulators mimicking the mass and dimensions of the company's next-generation Starlink Version 3 broadband satellites.

This time—Starship's 13th full-scale test flight and the second to use SpaceX's newest version of Starship—technicians have installed 20 Starlink V3 satellites into the ship's deployer, a system of pulleys and cables designed to eject a stack of satellites one at a time through an opening on the side of the spacecraft. The satellites will not be part of SpaceX's operational network, but engineers will attempt to briefly establish laser communication links between the Starlink V3s and other spacecraft flying in low-Earth orbit. If successful, these links will validate Starlink V3's interoperability with SpaceX's previous generation of Starlink satellites.

Read full article

Comments

© SpaceX

The next test flight of SpaceX's Starship spacecraft and Super Heavy booster could take off as soon as Thursday, and much of the hour-long mission will look a lot like the last Starship flight in May.

But there are a few key differences for this launch, set to occur during a launch window that opens at 5:45 pm CDT (22:45 UTC) on Thursday. The most notable change is the inclusion of real, functioning Starlink satellites inside Starship's cargo bay. SpaceX previously tested the ship's payload deployment mechanism using simulators mimicking the mass and dimensions of the company's next-generation Starlink Version 3 broadband satellites.

This time—Starship's 13th full-scale test flight and the second to use SpaceX's newest version of Starship—technicians have installed 20 Starlink V3 satellites into the ship's deployer, a system of pulleys and cables designed to eject a stack of satellites one at a time through an opening on the side of the spacecraft. The satellites will not be part of SpaceX's operational network, but engineers will attempt to briefly establish laser communication links between the Starlink V3s and other spacecraft flying in low-Earth orbit. If successful, these links will validate Starlink V3's interoperability with SpaceX's previous generation of Starlink satellites.

Read full article

Comments

© SpaceX

It wasn't easy to find anyone outside of SpaceX clamoring for a rocket like Starship just 10 years ago. Today, the space industry can't wait for Starship to finally deliver.

With a payload capacity of more than 100 metric tons (220,000 pounds) to low-Earth orbit, SpaceX's new rocket is changing the thinking of just about everyone in the space industry. With the unrealized but potentially game-changing benefits of refueling, Starship could carry the same amount of payload to higher orbits, the Moon, or Mars.

It's important to note that Starship is still very much in its experimental phase, far from proving Elon Musk's loftiest claims about what it can do. Still, NASA and the US military are considering novel ways to use Starship to fly to the Moon or transport cargo to far-flung war zones. Scientists are eager to use its enormous volume to launch giant space telescopes. Competitors are taking notice. China, the strongest strategic adversary America has ever faced, is looking for its own Starship. Now, some US satellite manufacturers are adapting for the substantial capacity of the world's most powerful rocket.

Read full article

Comments

© SpaceX

It wasn't easy to find anyone outside of SpaceX clamoring for a rocket like Starship just 10 years ago. Today, the space industry can't wait for Starship to finally deliver.

With a payload capacity of more than 100 metric tons (220,000 pounds) to low-Earth orbit, SpaceX's new rocket is changing the thinking of just about everyone in the space industry. With the unrealized but potentially game-changing benefits of refueling, Starship could carry the same amount of payload to higher orbits, the Moon, or Mars.

It's important to note that Starship is still very much in its experimental phase, far from proving Elon Musk's loftiest claims about what it can do. Still, NASA and the US military are considering novel ways to use Starship to fly to the Moon or transport cargo to far-flung war zones. Scientists are eager to use its enormous volume to launch giant space telescopes. Competitors are taking notice. China, the strongest strategic adversary America has ever faced, is looking for its own Starship. Now, some US satellite manufacturers are adapting for the substantial capacity of the world's most powerful rocket.

Read full article

Comments

© SpaceX

In a groundbreaking study published in Nature Communications, researchers have illuminated a critical link between Fusobacterium periodonticum and the progression of colorectal cancer, unveiling a complex biochemical pathway that involves decanoic acid-mediated neutrophil chemotaxis. This discovery adds a significant piece to the puzzle of how microbial influences within the gut microenvironment contribute to tumorigenesis, potentially opening new avenues for targeted therapies against colorectal cancer.

Colorectal cancer is among the leading causes of cancer-related mortality worldwide, and although genetic factors and lifestyle influences have been extensively studied, the role of the gut microbiota has only recently come to the forefront. The study conducted by Jia, Jiang, Gong, and colleagues delves deeply into the mechanistic interactions between a specific bacterial species, Fusobacterium periodonticum, and the host immune landscape, highlighting a novel metabolic crosstalk that accelerates tumor development.

Fusobacterium periodonticum, traditionally associated with oral biofilms and periodontal disease, has increasingly been detected in colorectal cancer tissues, but its precise role in cancer biology remained unclear until now. The researchers demonstrate that this bacterium secretes decanoic acid, a medium-chain fatty acid, which acts as a chemoattractant, mobilizing neutrophils to the site of tumor inception. Neutrophils, while pivotal in innate immunity, paradoxically can induce pro-tumorigenic inflammation under certain conditions.

By employing an integrative approach combining metagenomic analyses, metabolomics, and in vivo murine models, the team traced the cascade from bacterial colonization to immune recruitment and revealed that decanoic acid engages specific chemokine receptors on neutrophils. This interaction fosters a microenvironment rich in inflammatory mediators, growth factors, and oxidative stress, all of which potentiate malignant transformation and tumor growth.

The significance of neutrophils in cancer progression is increasingly recognized, but the finding that a bacterial metabolite directly drives neutrophil chemotaxis in the colorectal milieu establishes a new paradigm. Unlike conventional chemoattractants, decanoic acid appears to uniquely modulate neutrophil behavior, enhancing their recruitment and activation state, which in turn exacerbates tissue remodeling and genomic instability within epithelial cells.

This intricate host-microbe dialogue also implicates metabolic dysregulation as a driving force. The elevated levels of decanoic acid in the tumor microenvironment underscore how bacterial metabolism intersects with host pathways, creating conditions unfavorable for normal tissue homeostasis and favorable for neoplastic transformation. The researchers adeptly demonstrate that blocking the receptors responsive to decanoic acid attenuates neutrophil infiltration and reduces tumor burden in experimental models, underscoring therapeutic potential.

Further dissection of the immune milieu revealed that neutrophils recruited by decanoic acid secrete a spectrum of cytokines and chemokines that recruit additional immune and stromal cells, contributing to a chronic inflammatory state. This inflammation not only supports tumor cell proliferation but also promotes angiogenesis and suppresses adaptive immune responses, thereby facilitating immune evasion.

The clinical implications of these findings are manifold. Understanding the role of Fusobacterium periodonticum and its metabolic products in colorectal tumorigenesis invites consideration of microbiota-targeted interventions. Strategies such as selective antibiotics, probiotics to restore microbial balance, or small molecules that inhibit decanoic acid signaling might serve as adjuncts to conventional chemotherapy or immunotherapy.

Indeed, the intersection between microbial ecology and cancer biology posits a compelling narrative wherein microorganisms are not mere bystanders but active participants orchestrating complex pathophysiological processes. The decanoic acid-driven recruitment of neutrophils exemplifies how microbial metabolites can hijack immune mechanisms, turning protective responses into facilitators of malignancy.

Moreover, the identification of decanoic acid as a pivotal mediator expands the landscape of oncogenic metabolites beyond the commonly studied short-chain fatty acids, introducing medium-chain fatty acids as critical players in tumor-immune dynamics. This underscores the importance of integrating metabolomic profiling in cancer research to uncover previously underappreciated biochemical pathways.

From a diagnostic perspective, elevated decanoic acid or markers of neutrophil activation within colorectal tissues or patient serum samples might serve as biomarkers for early detection or risk stratification. The specificity imparted by the involvement of Fusobacterium periodonticum offers a microbiota-based signature that could refine personalized medicine approaches.

The authors highlight the translational potential of targeting the decanoic acid-neutrophil axis. For instance, developing receptor antagonists or neutralizing antibodies that mitigate neutrophil chemotaxis may diminish pro-tumor inflammation without compromising host defense. Such therapies could synergize with immunomodulatory agents to reinvigorate anti-tumor immunity.

Beyond colorectal cancer, these findings prompt reevaluation of Fusobacterium periodonticum’s role in other inflammatory or neoplastic conditions associated with mucosal surfaces. The paradigms unveiled here may be applicable to understanding microbiota-driven pathogenesis in other cancers or chronic inflammatory diseases, hinting at broader biomedical relevance.

The robust experimental framework of this study, which ranges from bacterial culture to patient-derived samples and genetically engineered mouse models, strengthens the causal link and positions it as a cornerstone for future investigations. The detailed mechanistic insights provide a platform for exploring combinatorial therapies that integrate microbial manipulation and immune modulation.

In sum, Jia et al. have charted a novel territory in cancer research by elucidating how a bacterial species long recognized for its role in oral health can influence colorectal carcinogenesis through a metabolite-mediated immune recruitment mechanism. This work exemplifies the power of interdisciplinary research bridging microbiology, immunology, and oncology to unravel complex disease processes.

As research continues to unravel the intricate dance between microbiota and host immunity, the elucidation of pathways like the decanoic acid-driven neutrophil chemotaxis reaffirms the critical role of the microbiome in health and disease. Ultimately, this knowledge holds promise for innovative cancer prevention strategies that target the microbial ecosystem alongside human cells.

The implications of this research resonate beyond the laboratory, raising compelling questions about dietary modulation, microbiome management, and personalized interventions that could transform cancer prognosis. Understanding the forces that drive tumorigenesis at the intersection of microbes and immune cells is not just an intriguing scientific pursuit but a critical step toward conquering a major human health burden.

Subject of Research:
The study focuses on the interaction between Fusobacterium periodonticum and neutrophil chemotaxis mediated by decanoic acid, with implications for colorectal tumorigenesis.

Article Title:
Fusobacterium periodonticum promotes colorectal tumorigenesis via decanoic acid-driven neutrophil chemotaxis.

Article References:
Jia, X., Jiang, L., Gong, Y. et al. Fusobacterium periodonticum promotes colorectal tumorigenesis via decanoic acid-driven neutrophil chemotaxis. Nat Commun (2026). https://doi.org/10.1038/s41467-026-74591-y

Image Credits: AI Generated

Amazon and several other non-geostationary satellite operators have formed a trade association to represent their fast-growing market, with SpaceX notably absent despite having by far the largest NGSO constellation.

The post NGSO trade association launches without industry giant SpaceX appeared first on SpaceNews.

Com mais de 155.000 observações reais de voos, o Starlink Flights identifica quais as companhias aéreas e aeronaves que já têm o serviço de internet via satélite da SpaceX instalado a bordo.

The post Starlink Flights: Descubra se o seu próximo voo tem WiFi da Starlink a bordo antes de embarcar appeared first on Tek Notícias.

Se você quer acessar a rede EchoLink no PC, conheça e veja como instalar o cliente EcoLink Qtel no Linux via Flatpak.

Leia o restante do texto "Como instalar o cliente EcoLink Qtel no Linux via Flatpak"

O post Como instalar o cliente EcoLink Qtel no Linux via Flatpak apareceu primeiro em Blog do Edivaldo - Informações e Notícias sobre Linux.

A CP – Comboios de Portugal lançou um projeto-piloto com tecnologia Starlink num Alfa Pendular, inserindo-se numa vaga global que já transformou a conectividade em dezenas de companhias aéreas e operadores ferroviários europeus.

The post CP acompanha tendência mundial e inicia testes de Internet por satélite Starlink nos comboios Alfa Pendular appeared first on Tek Notícias.

In a groundbreaking study that promises new horizons in the treatment of hypertension-associated cognitive decline, researchers have uncovered the potential of hydrogen sulfide (H₂S) as a therapeutic agent to alleviate spatial learning deficits. This novel work, spearheaded by Kumar, Mishra, and Goswami, delves into the intricate molecular pathways by which H₂S mediates neuroprotection in the context of angiotensin II-induced hypertension, revealing the suppression of endothelial NOX2 and subsequent neuroinflammatory cascades as a key mechanism. These findings not only expand our understanding of the pathophysiological link between hypertension and cognitive impairment but also highlight the therapeutic promise of gaseous signaling molecules in neurovascular health.

Hypertension, a pervasive cardiovascular disorder, has long been implicated in cognitive decline and an increased risk of neurodegenerative diseases. The relationship between elevated blood pressure and impaired spatial learning is complex, involving multifactorial processes such as oxidative stress, endothelial dysfunction, and neuroinflammation. This study addresses the critical gap in understanding how these pathological mechanisms interplay and how specifically targeting them might prevent or reverse cognitive deficits commonly observed in hypertensive patients.

A central player in this pathology is the NADPH oxidase 2 (NOX2), an enzyme prominently expressed in the endothelium and a major producer of reactive oxygen species (ROS). Overactivation of NOX2 leads to excessive oxidative stress, which in turn triggers inflammatory pathways damaging neuronal networks essential for spatial learning and memory. The research identifies NOX2 not merely as a bystander but as a pivotal driver of the neuroinflammatory processes exacerbated by angiotensin II, a peptide hormone central to blood pressure regulation.

The role of hydrogen sulfide in cellular signaling has emerged as a vibrant area of research, particularly its cytoprotective effects in the cardiovascular system. This gasotransmitter is synthesized endogenously and exerts diverse biological functions, including vasodilation, anti-apoptotic actions, and antioxidant effects. Intriguingly, H₂S is shown to modulate the activity of endothelial cells, suggesting a potential intersection between vascular health and cognitive function. The study meticulously explores how administrating exogenous H₂S can modulate endothelial responses in hypertensive models.

Utilizing advanced in vivo models of angiotensin II-induced hypertension, the researchers employed comprehensive behavioral assays to evaluate spatial learning and memory deficits. These studies revealed pronounced impairments consistent with neuroanatomical and functional alterations within the hippocampus, a brain region integral to spatial navigation. The administration of hydrogen sulfide donors elicited a marked reduction in cognitive deficits, underscoring the functional significance of H₂S in this setting.

At the molecular level, the investigation demonstrated that hydrogen sulfide suppresses NOX2 expression and activity in endothelial cells exposed to hypertensive stimuli. This effect culminates in reduced oxidative stress and diminished activation of downstream pro-inflammatory mediators such as cytokines and microglial markers. The attenuation of these pathways underscores the multifaceted influence of H₂S in preserving the integrity of the neurovascular unit under conditions of elevated blood pressure.

Moreover, this research sheds light on the intricate interaction between endothelial dysfunction and neuroinflammation, which has emerged as a critical nexus in the pathogenesis of cognitive decline. The findings suggest that endothelial-derived oxidative stress and inflammation contribute to microglial activation and neuronal damage, processes that H₂S effectively counters. This adds a new layer to our conceptual framework of how vascular health dictates neural outcomes.

From a translational perspective, the study offers compelling evidence supporting hydrogen sulfide donors as viable therapeutic agents. The modulation of NOX2 and inflammatory pathways by H₂S paves the way for pharmacological strategies aimed at mitigating hypertension-induced neural deficits without directly targeting blood pressure itself. Such approaches could complement existing antihypertensive therapies, broadening the arsenal against cognitive impairment in hypertensive populations.

Importantly, the safety profile and physiological relevance of hydrogen sulfide administration were addressed, with the researchers noting minimal adverse effects in the animal models. This aspect is crucial given the dual nature of H₂S, which at elevated concentrations can be toxic. The study’s careful titration of dose and delivery methods serves as a valuable blueprint for future clinical investigations.

Another notable contribution of the study is its use of molecular imaging and histological techniques that corroborate the behavioral findings. These methodologies revealed decreased markers of oxidative damage and neuroinflammation in treated samples, providing robust evidence that H₂S exerts its effects through tangible cellular and tissue-level changes. Such multimodal validation strengthens the case for H₂S’s integrative role in neurovascular protection.

The work also prompts intriguing questions about the broader implications of gasotransmitters in neurodegeneration. Given the overlapping mechanisms of vascular and neurodegenerative diseases, the therapeutic modulation of gas signaling pathways may represent a paradigm shift in managing multifactorial brain disorders. This article can stimulate further research into the cross-talk between vascular function and cognitive health, championing hydrogen sulfide and related molecules as key modulators.

Furthermore, the research adds to the growing body of literature underscoring the critical importance of the endothelial interface in neural function. By targeting endothelial NOX2, hydrogen sulfide indirectly protects neural cells from oxidative and inflammatory insults, delineating an elegant mechanism wherein vascular and neural health are inextricably linked. This insight encourages a more integrated approach to cardiovascular and cognitive care.

As hypertension continues to affect millions worldwide and remains a predominant risk factor for dementia and stroke, therapies that confer cognitive resilience hold immense value. Hydrogen sulfide’s ability to mitigate vascular and neural insults in this context may redefine therapeutic goals, prioritizing the preservation of cognitive faculties alongside blood pressure control. Such dual-focused treatment paradigms could dramatically improve patient outcomes.

In conclusion, the pioneering study by Kumar and colleagues stands out as a beacon in the endeavor to unravel and counteract hypertension-induced cognitive dysfunction. By elucidating the molecular substrates by which hydrogen sulfide ameliorates endothelial oxidative stress and neuroinflammation, the research opens a new therapeutic frontier. As the science community advances these findings, we may soon witness the integration of gasotransmitter-based interventions in clinical practice, offering hope for millions at risk of cognitive decline associated with hypertension.

Subject of Research:
Article Title:
Article References: Kumar, G., Mishra, S., Goswami, S. et al. Hydrogen sulfide mitigates spatial learning deficits in angiotensin II-Induced hypertension via inhibition of endothelial NOX2 and neuroinflammation. Transl Psychiatry (2026). https://doi.org/10.1038/s41398-026-04178-0
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41398-026-04178-0

Why, in the age of Starlink and Low Earth Orbit satellites, is the British state despoiling the countryside with telegraph poles, asks Joanna Gray. It's 2026 FFS.

The post Why is the British State Despoiling the Countryside with Telegraph Poles in 2026? appeared first on The Daily Sceptic.

In a groundbreaking study that illuminates the intricate interplay between the immune system and mental health, researchers have unveiled a pivotal molecular mechanism linking atopic dermatitis, a chronic inflammatory skin condition, to depressive symptoms. Published in Translational Psychiatry, the study spearheaded by Matsuda, Muko, Moon, and colleagues highlights the role of blood interleukin-6 (IL-6) as a critical trigger for depression in a mouse model replicating human atopic dermatitis. This revelation not only deepens our understanding of the biological pathways that connect systemic inflammation with neuropsychiatric manifestations but may also catalyze novel therapeutic strategies targeting inflammatory cytokines to alleviate depression associated with chronic inflammatory diseases.

Atopic dermatitis, commonly known as eczema, affects millions worldwide and is notoriously characterized by episodic, intense itching and inflammation of the skin. While predominantly studied for its cutaneous symptoms, accumulating clinical evidence has shown that patients with atopic dermatitis frequently exhibit comorbid psychiatric issues, such as anxiety and depression. However, the mechanistic underpinnings that establish a causal link between skin inflammation and mood disorders have remained elusive. The present study bridges this knowledge gap by focusing on IL-6, a well-recognized pro-inflammatory cytokine implicated in diverse physiological and pathological processes, including immune regulation, infection response, and now, neuropsychiatric disorders.

The research involved a sophisticated mouse model genetically engineered to mimic human atopic dermatitis, enabling the authors to observe both peripheral immune responses and central nervous system changes associated with chronic skin inflammation. Over the course of the experiments, blood samples were analyzed for inflammatory mediators, revealing significantly elevated IL-6 levels in mice developing atopic dermatitis-like symptoms. This systemic rise in IL-6 was temporally correlated with the onset of depressive-like behaviors, such as reduced motivation and social withdrawal, as assessed by established behavioral paradigms.

Critically, the investigators did not stop at correlation but probed the causality of this relationship through a series of mechanistic experiments. By pharmacologically blocking IL-6 signaling pathways, they observed a remarkable attenuation of depressive symptoms in affected mice, without altering the severity of the skin lesions. This dissociation suggests that blood IL-6 acts as a signaling molecule communicating peripheral inflammatory status to the brain, thereby directly influencing mood and behavior independently from the physical discomfort of skin irritation.

Delving deeper into the neurobiological impact of IL-6, the study explored how elevated systemic IL-6 might affect brain regions crucial for mood regulation. Using immunohistochemistry and gene expression analyses, the researchers identified activation of microglial cells, the brain’s resident immune cells, within the hippocampus and prefrontal cortex—areas heavily implicated in depression. This microglial activation was associated with increased production of local inflammatory mediators and suppressed neurogenesis, factors known to contribute to depressive pathology, thus mapping a detailed pathway from peripheral inflammation to central nervous system dysfunction.

The implications of these findings are profound for clinical practice. Current treatments for atopic dermatitis largely focus on topical therapies and immunosuppressants aimed at skin symptoms, often neglecting the neuropsychiatric burden experienced by patients. Recognizing IL-6 as a critical mediator suggests that adjunctive therapies targeting systemic inflammation—including monoclonal antibodies against IL-6 or its receptor—could not only ameliorate the physical manifestations of atopic dermatitis but also alleviate its psychological sequelae.

Moreover, given that IL-6 is implicated in a broad spectrum of inflammatory conditions beyond atopic dermatitis, these insights may extend to other chronic diseases characterized by elevated inflammatory markers and comorbid depression, such as rheumatoid arthritis or inflammatory bowel disease. This study adds weight to the emerging paradigm that psychiatric disorders in systemic illnesses are not mere psychological reactions but integral components of pathophysiology driven by immune dysregulation.

The team’s approach to modeling human disease in mice allowed for precise temporal and causal investigations otherwise unfeasible in human populations. Nevertheless, future studies will need to validate these mechanistic insights in clinical cohorts and determine the safety and efficacy of IL-6-targeted interventions for depressive symptoms. Given IL-6’s pleiotropic roles, therapeutic strategies will require nuanced modulation to avoid impairing essential immune functions.

This research also underscores the importance of interdisciplinary approaches combining dermatology, immunology, and psychiatry to unravel complex multi-system diseases. As the boundaries between physical and mental health blur at the molecular level, the integration of comprehensive immune profiling in clinical psychiatry could revolutionize diagnosis and personalized treatment, ultimately improving outcomes for patients with inflammatory and mood disorders alike.

On a molecular scale, the role of IL-6 extends beyond inflammation. It is involved in the hypothalamic-pituitary-adrenal (HPA) axis regulation, known to mediate stress responses. Elevated IL-6 may contribute to dysregulation of glucocorticoid signaling, further exacerbating depressive symptoms. The study’s findings suggest that IL-6 might be a nexus point linking immune activation, neuroendocrine disturbance, and behavioral changes, offering a unifying framework to understand inflammation-induced depression.

The study also utilized advanced transcriptomic analyses to map downstream signaling cascades elicited by IL-6 in neuronal and glial populations. These analyses identified upregulation of genes associated with synaptic remodeling, oxidative stress, and apoptotic pathways, reflecting neurotoxic effects that can disrupt neural circuitry. Such molecular signatures provide valuable biomarkers for monitoring disease progression and therapeutic responses.

One of the particularly compelling aspects of the findings is the observation that IL-6 blockade improved depressive-like behavior without reducing skin inflammation, indicating that mood symptoms can be directly modulated independently from the peripheral manifestations of atopic dermatitis. This observation challenges conventional clinical assumptions and opens avenues for selective treatment of comorbid depression in inflammatory conditions without necessarily altering the primary disease state.

The study’s methodological rigor—combining behavioral assays, cytokine profiling, histological analyses, and pharmacological interventions—sets a new standard for research into inflammation-driven psychiatric disorders. It reflects a shift from correlative clinical observations to mechanistic clarity, paving the way for targeted, mechanism-based therapies rather than symptomatic treatments.

Furthermore, these results prompt us to reconsider the diagnostic criteria for depression in patients with chronic inflammatory diseases. The presence of elevated IL-6 (and potentially other cytokines) might help stratify patients who could benefit from immunomodulatory approaches, thereby personalizing treatment and improving prognosis.

In conclusion, the elucidation of blood IL-6 as a critical trigger of depressive symptoms in atopic dermatitis represents a significant leap forward in deciphering the biological links between chronic inflammation and mental health. As research progresses from bench to bedside, these insights hold tremendous promise for transforming the lives of millions suffering from the dual burdens of inflammatory skin disease and mood disorders, moving the needle towards integrated and effective therapeutic paradigms.

---

Subject of Research:
The study investigates the mechanistic role of blood interleukin-6 (IL-6) in triggering depressive symptoms in a mouse model of human atopic dermatitis, exploring the intersection of systemic inflammation and neuropsychiatric manifestations.

Article Title:
Blood IL-6 is a critical trigger of depressive symptoms in a mouse model for human atopic dermatitis.

Article References:
Matsuda, K., Muko, R., Moon, C. et al. Blood IL-6 is a critical trigger of depressive symptoms in a mouse model for human atopic dermatitis. Transl Psychiatry (2026). https://doi.org/10.1038/s41398-026-04211-2

Image Credits:
AI Generated

DOI:
https://doi.org/10.1038/s41398-026-04211-2

Jio Platforms, which owns India’s largest telco, is looking to lease broadband capacity from satellite constellations to jumpstart its own sovereign LEO network in the country.

The post India’s Jio lays out sovereign LEO constellation plan ahead of IPO appeared first on SpaceNews.

SpaceX reportedly hit out at a European Commission (EC) plan for distributing satellite spectrum across the bloc, warning current proposals could directly impact connectivity with mobile devices.

Bloomberg reported it had seen a statement from Elon Musk’s rocket company which takes aim at an EC plan to offer only a third of its 2GHz frequency band to companies outside the European Union (EU), keeping the remaining amount for those based in the bloc.

The outlet said the proposal effectively excludes foreign companies, like SpaceX, from offering satellite services to governments and will directly impact the expansion of its Starlink connectivity play.

SpaceX has established a presence in Europe, striking partnerships with European operators including Deutsche Telekom and Orange to offer Starlink D2D services to customers.

However, SpaceX said the EC’s plans will split spectrum “in virtually unusable sub-divided parts”.

It apparently added intentions are inconsistent with international regulations and do not adhere to “Europe’s international obligations and economic reality”.

Ukraine concern
Another bone of contention is an EC aim to reserve airwaves for the Europe IRIS2 constellation, with SpaceX arguing this could risk poorer connectivity in Ukraine where Starlink has been used during the country’s war with Russia.

“The proposal creates a significant likelihood that Europeans will be left without direct-to-device satellite services or that new European operations will create global interference problems, including to emergency services like those in Ukraine,” read the statement.

When outlining the plans, EC EVP Henna Virkkunen said earmarking allocations to local operators would encourage diversification of suppliers and incentivise entry into the market.

She also said the 2GHz band was vital for boosting Europe’s competitiveness, security, and fits in with an ongoing drive around technology sovereignty.

The post SpaceX slams Europe satellite spectrum plan appeared first on Mobile World Live.

The upper stage from a commercial Chinese rocket that launched last week has broken apart in space, spreading debris in a heavily trafficked part of low-Earth orbit home to the International Space Station and a significant portion of SpaceX's Starlink broadband network.

The breakup occurred shortly after the Zhuque-2E rocket reached orbit on June 9 with two satellites providing direct-to-cell communications, perhaps around the time the upper stage was expected to perform a disposal burn. The US Space Force confirmed the breakup event in a post on space-track.org, a website used by the military to distribute orbit data to the public.

"The tracked pieces are being incorporated into routine conjunction assessment to support spaceflight safety," the Space Force wrote in an advisory. "There are currently no threats to human spaceflight. Analysis is ongoing."

Read full article

Comments

© Wang Heng/Xinhua via Getty Images

SpaceX raised $75 billion in an historic initial public offering (IPO), pricing 555.6 million shares at $135 each with trading set to begin later today (12 June) on the Nasdaq stock exchange.

The listing is the biggest of all time, more than doubling the value of Saudi company Aramco’s stock market debut in 2019 which raised around $29 billion.

In a filing, SpaceX stated it has granted underwriters a 30-day option to purchase an additional 83 million shares, which could increase the total fundraising to $86 billion at a $1.78 trillion valuation.

Financial Times reported Elon Musk’s rocket, satellite and AI company drew orders more than three times the amount on offer, with demand coming from huge asset managers, gulf sovereign wealth funds, hedge funds and retail investors.

According to the outlet, individual investors placed orders for more than $100 billion and will be allocated around 20% to 25% of the total shares sold.

Musk is apparently keen to place smaller shareholders at the centre of SpaceX’s ownership, leaving fewer shares available for big companies and accounts that tend to be prioritised in IPOs.

Through the funds raised, SpaceX is to pump cash into a plan to establish AI data centres in space, a Musk vision that centres on overcoming energy limitations on earth. The company is also plotting new satellite constellations to fuel Starlink, while it will also pay down debt after taking a $20 billion bridging loan in March.

FT added the $1.78 trillion market value makes SpaceX the priciest of the world’s top 10 valuable companies, with its shares trading at 92 times its $19 billion revenue in 2025.

Following SpaceX’s market debut, OpenAI and Anthropic have also announced intentions to also hold a listing.

The post SpaceX raises $75B in record-breaking IPO appeared first on Mobile World Live.

A empresa espacial de Elon Musk fixou o preço a 135 dólares por ação, numa avaliação de 1,77 biliões de dólares que "pulveriza" todos os recordes anteriores. As ações da SPCX estreiam-se hoje às 14:30 (hora de Portugal continental) no Nasdaq.

The post SpaceX estreia-se hoje na bolsa com o maior IPO da história. Elon Musk pode tornar-se no primeiro trilionário do mundo appeared first on Tek Notícias.

Problems with Starlink's India expansion could challenge SpaceX's IPO growth story.

Counterpoint Research co-founder and research VP Neil Shah warned reports India hit the brakes on licensing SpaceX’s Starlink service could be bad news for the company’s IPO.

In a post on X, the analyst pointed to the scale of the Indian market along with highlighting the connection between revenue generation and investment in space projects.

Shah argued these elements are all at risk if India halts approvals for the launch of commercial Starlink services, in turn putting a “spanner in the wheel” of SpaceX’s pending IPO.

The reported timing of India’s intentions is “really bad”, Shah wrote.

Counterpoint Research’s executive was responding to a Bloomberg article indicated India had put approval processes on ice. Authorities are concerned over reports unlicensed Starlink terminals had been used in Iran, the news outlet stated.

Shah added India’s “highly sensitive, contested borders” are another factor, making the “threat of unmonitored, untraceable satellite terminals operating on its soil” without domestic oversight an “absolute red line”.

Bloomberg noted India’s population is the biggest in the world: Shah put the proportion at 40%.

The news outlet highlighted Lauren Dreyer, VP of Business Operations at Starlink, used X to explain the company “remains in active and productive discussions” with India’s government.

Dreyer branded the speculation “misleading” and “based on unsubstantiated claims from anonymous sources”.

Shah noted the potential licensing fracas indicates sovereignty assurances are emerging as an important requirement for privately-held companies seeking to deliver space-based services in “key economies”, pointing to moves by China and the European Union covering low Earh orbit services as examples.

Bloomberg stated SpaceX is preparing an expected historic listing on 12 June.

The post India Starlink setback could impact SpaceX IPO appeared first on Mobile World Live.